An experimental study of the use of hyperbaric oxygen to reduce the side effects of radiation treatment for malignant disease

Williamson, Raymond

doi:10.1016/j.ijom.2007.03.003

Cited by 27 publications

(18 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many studies have examined the efficacy of increasing tissue oxygen concentration to promote oxidation of radicals produced by low-LET irradiation to cancer cells/tissue, but few therapeutic gains have thus far been observed [18][19][20]. Besides increasing tissue oxygen concentrations, it is important to inactivate antioxidative enzymes, such as peroxidase and catalase, which protect cancer cells from oxidative stress.…”

Section: Discussionmentioning

confidence: 99%

Therapeutic response to a new enzyme-targeting radiosensitization treatment (KORTUC-SC) for patients with chemotherapy-resistant supraclavicular lymph node metastasis

Aoyama¹,

Ogawa²,

Kubota³

et al. 2013

J Cancer Res Ther

View full text Add to dashboard Cite

IntroductionLinear accelerator (Linac)-generated high-energy X-rays and electron beams that are generally used for radiotherapy are low-linear energy transfer (LET) forms of radiation, and have a relatively weak biological effect. High-energy X-rays and electron beams have minimal effects on tumors that contain many hypoxic cancer cells and/or large amounts of antioxidative enzymes. Examples of such tumors include malignant melanoma, various types of sarcomas, glioblastoma multiforme, and most relatively large tumors more than several centimeters in their long diameter. Thus, effective treatment of these tumors requires strategies to re-oxygenate hypoxic tumor cells and to inhibit antioxidative enzymes. Therapeutic response to a new enzyme-targeting radiosensitization treatment (KORTUC-SC) for patients with chemotherapy-resistant supraclavicular lymph node metastasis AbstractWe have developed a new radiosensitizer containing hydrogen peroxide and sodium hyaluronate, part of a method we call "KORTUC II". This study aimed to evaluate the safety and effectiveness of KORTUC II specifically for patients with chemotherapy-resistant supraclavicular lymph node metastasis (KORTUC-SC). Twelve patients were enrolled after providing fully informed written consent. Most of the patients underwent PET-CT examinations prior to and 3-8 months after KORTUC-SC, and every 6 months thereafter if possible. The patients' age ranged from 58 to 77. The radiotherapy regimen was 4 Gy/ fraction, 3 fractions/ week, for 4 weeks, and the total dose was 48 Gy. The injection of 3 to 6 mL of the agent was started from the fifth radiotherapy fraction, and it was performed twice a week under ultrasonographic guidance. Therapeutic effects were evaluated by PET-CT examinations performed before and after KORTUC-SC treatment. The patients were well tolerated with minimal adverse effects. Of the 12 patients, 4, 5, 2 and 1 patient showed complete response, partial response, stable disease and progressive disease, respectively. The overall survival rate was 83% at 1 year and 75% at 2 years. The mean duration of follow-up at the end of February 2011 was 35.1 months. Based on the PET-CT studies, remarkable therapeutic effects of the KORTUC II treatment were clearly identified. The treatment outcomes were satisfactory. Welldesigned, prospective, randomized, clinical trials are needed to confirm the therapeutic efficacy of KORTUC-SC.

show abstract

Section: Discussionmentioning

confidence: 99%

Therapeutic response to a new enzyme-targeting radiosensitization treatment (KORTUC-SC) for patients with chemotherapy-resistant supraclavicular lymph node metastasis

Aoyama¹,

Ogawa²,

Kubota³

et al. 2013

J Cancer Res Ther

View full text Add to dashboard Cite

show abstract

“…HBOT has been used clinically to treat radiation-induced damage for many years, but there remain opposing views on its efficacy [1][2][3][4][5][6]9 . This reflects the need for more in-depth animal experimental research on HBOT.…”

Section: Discussionmentioning

confidence: 99%

A hyperbaric oxygen chamber for animal experimental purposes

Djasim

Spiegelberg

Wolvius

et al. 2012

International Journal of Oral and Maxillofacial Surgery

View full text Add to dashboard Cite

“…LRTI results in a progressive deterioration characterised by a reduced vascularity and increased fibrosis until there is insufficient oxygen supplied to sustain normal tissue function [10]. The use of HBOT is based on the premise that increased oxygen tissue tension aids wound healing by increasing the hypoxic gradient and stimulating angiogenesis and fibroblast differentiation [11]. Potential mechanisms of action of HBOT include increased tissue oxygenation, reduction of oedema and capillary angiogenesis [12].…”

Section: Discussionmentioning

confidence: 99%

Hyperbaric oxygen therapy for late radiation tissue injury in gynaecological patients

Rud

Bjørgo

Kristensen

et al. 2009

Support Care Cancer

View full text Add to dashboard Cite

show abstract

An experimental study of the use of hyperbaric oxygen to reduce the side effects of radiation treatment for malignant disease

Cited by 27 publications

References 16 publications

Therapeutic response to a new enzyme-targeting radiosensitization treatment (KORTUC-SC) for patients with chemotherapy-resistant supraclavicular lymph node metastasis

Therapeutic response to a new enzyme-targeting radiosensitization treatment (KORTUC-SC) for patients with chemotherapy-resistant supraclavicular lymph node metastasis

A hyperbaric oxygen chamber for animal experimental purposes

Hyperbaric oxygen therapy for late radiation tissue injury in gynaecological patients

Contact Info

Product

Resources

About